Conclusion

This report introduces the potentially beneficial effects of infliximab in the treatment of COVID-19 patients. Inhibition of TNF-α via infliximab may reduce the COVID-19 disease progression. The ventilator may increase complications in the COVID-19 patient, so TNF-α inhibition should occur before the ventilator’s use. Large randomized study samples are necessary to investigate the efficacy of infliximab, and combinations with other immunomodulating drugs like Anakinra or chemokine inhibitors may reveal new treatment guidelines for COVID-19 patients.